Purdue Pharma

Purdue Pharma invests in oncology R&D

Wednesday, November 15, 2017

Purdue Pharma announced completion of significant oncology related investments as part of its ongoing efforts to diversify its scientific research into areas of high unmet medical need. Through these investments, executed over a multi-year period and capped recently in 2017, Purdue is establishing a portfolio of drug candidates with the potential to deliver new cancer therapies to patients within the next five years.

[Read More]

Purdue Pharma appoint Dr. Craig Landau president and CEO

Monday, June 26, 2017

The Board of Directors of the independently associated worldwide Purdue/Napp/Mundipharma network of companies announces that Dr. Craig Landau is appointed president and CEO for the U.S. operations, Purdue Pharma, headquartered in Stamford, Connecticut, with immediate effect, and will retain responsibility for Purdue Pharma (Canada).

[Read More]

Digital clinical research is nearing a tipping point

Monday, January 18, 2016

The Pulse on Global Trials by Matthew Howes

Since I started writing this column two years ago, clinical research has seen modest improvements in failure rates of late stage trials, but for the most part drug development remains unnecessarily expensive and inefficient. 

[Read More]